论文部分内容阅读
作者认为以往对类固醇药物治疗格林-巴利(Guillain-Barré)综合征的疗效评价多是根据非对照性试验或回顾性分析作出的,因此其疗效仍是可疑的。本文报告用强的松龙治疗本病一次多中心的随机对照试验。强的松龙治疗组(以下简称治疗组)21例,对照组19例。两组病人性别、年龄、发病至入院的时间、以及入院时的病情等均相似。强的松龙剂量:成人开始时60mg/日,服1周后改40mg/日,服4天,后30mg/日,服3天,以后再减量或遵医嘱。小儿按年龄减量。疗效评定:将病残程度分为0～6度,入院时以及在以后的1年内多次定期评定出每例病人的病残“度数”。结果治疗组病情改善不及对照组,有显著性差异(P<0.05)。治疗组有1例死于呼吸衰竭,该组1年以后有6例病人有明显的病残(2“度”或2
The authors concluded that the previous evaluation of the efficacy of steroid therapy in Guillain-Barré syndrome was based mostly on uncontrolled or retrospective analysis and therefore the efficacy was still questionable. This article reports a multicenter randomized controlled trial of prednisolone in the treatment of this disease. Prednisolone treatment group (hereinafter referred to as treatment group) 21 cases, control group 19 cases. The two groups of patients, gender, age, onset to admission time, and the condition at admission were similar. Prednisolone Dosage: Adult at the beginning of 60mg / day, change 1 week after the change 40mg / day, serving 4 days, after 30mg / day, serving 3 days, then reduce or follow the doctor’s advice. Children by age reduction. Efficacy assessment: the degree of illness and disability is divided into 0 to 6 degrees, at admission and in the next one year several times regularly to assess each patient’s sickness “degree.” Results The treatment group improved less than the control group, there was a significant difference (P <0.05). One patient died of respiratory failure in the treatment group, and six patients in the group had significant morbidity (2 “degrees” or 2